AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31880284 — intervention group
Group type: COMPARATOR
Intervention: OFD alone
Number of subjects: 45
Study 31880284 — intervention group
Group type: EXPERIMENTAL
Intervention: T-PRF and GTR
Number of subjects: 45
Study 31046185 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy including desensitization maneuvers of the central nervous system
Number of subjects: 120
Study 31046185 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 120
Study 28859114 — intervention group
Group type: EXPERIMENTAL
Intervention: Channeled video laryngoscope with pre-loaded endotracheal tube
Number of subjects: 46
Study 28859114 — intervention group
Group type: COMPARATOR
Intervention: Curved Macintosh blade video laryngoscope (control)
Number of subjects: 46
Study 26084809 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with sorafenib
Number of subjects: 223
Study 26084809 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine with placebo
Number of subjects: 223
Study 23784075 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Skills Training program (21 one-hour sessions in the first year and 12 one-hour sessions in the second year)
Number of subjects: 1048
Study 23784075 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Skills Training program
Number of subjects: 1048
Study 23784075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education or preventive sessions)
Number of subjects: 1048
Study 21925959 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review intervention delivered by pharmacists
Number of subjects: 342
Study 21925959 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 342
Study 19587607 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-Blockers
Number of subjects: 738
Study 19587607 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 738
Study 19587607 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 738
Study 19587607 — intervention group
Group type: COMPARATOR
Intervention: Awareness
Number of subjects: 738
Study 19587607 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure control
Number of subjects: 738
Study 16625984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexibuprofen (400 mg t.i.d for 3 days, then 400 mg b.i.d for 11 days)
Number of subjects: 60
Study 16625984 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (800 mg t.i.d for 3 days, then 800 mg b.i.d for 11 days)
Number of subjects: 60
Study 16625984 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (50 mg t.i.d for 3 days, then 50 mg b.i.d for 11 days)
Number of subjects: 60
Study 16625984 — intervention group
Group type: COMPARATOR
Intervention: All groups (Dexibuprofen, Ibuprofen, Diclofenac)
Number of subjects: 60
Study 15630183 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosmarinic acid (RA) 200 mg or 50 mg
Number of subjects: 0
Study 15630183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15630183 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosmarinic acid (RA)
Number of subjects: 0
Study 11395032 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 54
Study 11395032 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 54
Study 9205786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime 2 g once daily (either intravenously or intramuscularly)
Number of subjects: 99
Study 8197240 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Number of subjects: 6
Study 8197240 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 6
Study 2891372 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-phenoxy-W-17, 18, 19, 20-tetranor PGE2 methyl sulfonylamide (three intramuscular injections of 0.5 mg at 3-h intervals)
Number of subjects: 473
Study 2891372 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 473
Study 29395279 — intervention group
Group type: EXPERIMENTAL
Intervention: OTO‐201 (ciprofloxacin otic suspension 6%) intraoperative injection
Number of subjects: 501
Study 29395279 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid patients
Number of subjects: 501
Study 29395279 — intervention group
Group type: COMPARATOR
Intervention: Previous Phase 3 trials
Number of subjects: 501
Study 28629473 — intervention group
Group type: COMPARATOR
Intervention: Intravenous phenytoin (20 mg/kg, maximum 2 g)
Number of subjects: 308
Study 28629473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam (40 mg/kg, maximum 2.5 g)
Number of subjects: 308
Study 26332900 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine-containing mouthwash (STRONG)
Number of subjects: 12
Study 26332900 — intervention group
Group type: COMPARATOR
Intervention: Non-chlorhexidine mouthwash (WEAK)
Number of subjects: 12
Study 26332900 — intervention group
Group type: COMPARATOR
Intervention: Deionised water (CON)
Number of subjects: 12
Study 23300238 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day antiretroviral regimen (zidovudine/lamivudine, tenofovir/emtricitabine, or lopinavir/ritonavir)
Number of subjects: 484
Study 23300238 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day antiretroviral regimen (zidovudine/lamivudine, tenofovir/emtricitabine, or lopinavir/ritonavir)
Number of subjects: 484
Study 23300238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 484
Study 20921467 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent therapy (paclitaxel 225 mg/m² and carboplatin AUC 6 every 3 weeks plus cetuximab 400 mg/m² loading dose followed by 250 mg/m² weekly for four cycles)
Number of subjects: 224
Study 20921467 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (paclitaxel-carboplatin for four cycles followed by cetuximab)
Number of subjects: 224
Study 20921467 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 224
Study 19099714 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO) at 15 ppm for 34.90 ± 16.41 hours
Number of subjects: 46
Study 19099714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iNO)
Number of subjects: 46
Study 19099714 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Number of subjects: 46
Study 17213687 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term air-conditioning exposure (S)
Number of subjects: 0
Study 17213687 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term air-conditioning exposure (L)
Number of subjects: 0
Study 17213687 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 12648193 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (M)
Number of subjects: 182
Study 12648193 — intervention group
Group type: EXPERIMENTAL
Intervention: Music in combination with therapeutic suggestions (M/TS)
Number of subjects: 182
Study 12648193 — intervention group
Group type: COMPARATOR
Intervention: Control (blank tape)
Number of subjects: 182
Study 10922094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral preparation (45 mL oral sodium phosphate and 10 mg bisacodyl)
Number of subjects: 250
Study 10922094 — intervention group
Group type: COMPARATOR
Intervention: Enema preparation (2 Fleet enemas and 10 mg bisacodyl)
Number of subjects: 250
Study 10922094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral preparation
Number of subjects: 250
Study 10922094 — intervention group
Group type: COMPARATOR
Intervention: Enema preparation
Number of subjects: 250
Study 8756233 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 50
Study 8756233 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 50
Study 8141211 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (500 mg three times daily for 7 days)
Number of subjects: 74
Study 8141211 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (500 mg four times daily for 7 days)
Number of subjects: 74
Study 3410567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate temperature at 35 degrees C
Number of subjects: 8
Study 3410567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium concentration at 139 mmol/l
Number of subjects: 8
Study 3410567 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile membrane
Number of subjects: 8
Study 3410567 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan membrane
Number of subjects: 8
Study 29613950 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood donation (whole blood donation)
Number of subjects: 57
Study 29613950 — intervention group
Group type: COMPARATOR
Intervention: Mock donation (control group)
Number of subjects: 57
Study 29613950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests (three tests)
Number of subjects: 57
Study 28929582 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention via WhatsApp (1 face-to-face session of 60 min and 4 virtual sessions of 30 min each)
Number of subjects: 62
Study 28929582 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention via WhatsApp
Number of subjects: 62
Study 26047059 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dot-probe protocol
Number of subjects: 108
Study 26047059 — intervention group
Group type: COMPARATOR
Intervention: Standard dot-probe protocol (control)
Number of subjects: 108
Study 24244435 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual experiences of young adolescent schoolgirls
Number of subjects: 120
Study 24244435 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual hygiene practices
Number of subjects: 120
Study 24244435 — intervention group
Group type: EXPERIMENTAL
Intervention: School attendance during menstruation
Number of subjects: 120
Study 24244435 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and physical support mechanisms
Number of subjects: 120
Study 21148631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) 3 g per night for five consecutive nights
Number of subjects: 16
Study 21148631 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 16
Study 21148631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB)
Number of subjects: 16
Study 18240042 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise group with self-initiated training
Number of subjects: 0
Study 18240042 — intervention group
Group type: COMPARATOR
Intervention: Intensive exercise group with scheduled intensive training
Number of subjects: 0
Study 18240042 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 18240042 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical mobility sub-scale of NHP
Number of subjects: 0
Study 16816220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (up to 60 mg/day)
Number of subjects: 235
Study 16816220 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (up to 200 mg/day)
Number of subjects: 235
Study 12705063 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective cyclooxygenase‐2 inhibitor (celexocib)
Number of subjects: 0
Study 12705063 — intervention group
Group type: COMPARATOR
Intervention: Non steroidal anti‐inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 12705063 — intervention group
Group type: COMPARATOR
Intervention: Aspirin®
Number of subjects: 0
Study 10831483 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg)
Number of subjects: 34
Study 10831483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8527613 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac 300 mg b.d.
Number of subjects: 24
Study 8527613 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg b.d.
Number of subjects: 24
Study 2175569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin E supplementation for 48 days before exercise
Number of subjects: 21
Study 2175569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6250823 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure (intermittent noise alternating between 99 dB (A) and 45 dB (A) for 2 hours)
Number of subjects: 7
Study 6250823 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure
Number of subjects: 7
Study 6250823 — intervention group
Group type: COMPARATOR
Intervention: Control (no noise exposure)
Number of subjects: 7
Study 31107542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose‐intensified radiotherapy plus capecitabine and oxaliplatin (CAPOX50)
Number of subjects: 316
Study 31107542 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy plus capecitabine (CAP45)
Number of subjects: 316
Study 31107542 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 316
Study 28002167 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg intravenously
Number of subjects: 120
Study 28002167 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg intravenously
Number of subjects: 120
Study 26226960 — intervention group
Group type: EXPERIMENTAL
Intervention: PQQ disodium salt (BioPQQ™) at an oral dosage of 20 mg/d for 12 weeks
Number of subjects: 29
Study 26226960 — intervention group
Group type: EXPERIMENTAL
Intervention: PQQ disodium salt (BioPQQ™) in high LDL-chol subgroup (baseline LDL-chol ≥140 mg/dL)
Number of subjects: 29
Study 26226960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 24013586 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 90
Study 24013586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training
Number of subjects: 90
Study 24013586 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training alone
Number of subjects: 90
Study 24013586 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 20593204 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk flexor and general strength (TFS) training
Number of subjects: 24
Study 20593204 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific motor control (SMC) training
Number of subjects: 24
Study 20593204 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 20077733 — intervention group
Group type: EXPERIMENTAL
Intervention: JEV‐I (PHK) vaccine
Number of subjects: 943
Study 20077733 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (Vero cell-derived JEV vaccine)
Number of subjects: 943
Study 17275282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg and droperidol 0.625 mg (combination)
Number of subjects: 120
Study 17275282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 120
Study 17275282 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 120
Study 17275282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17275282 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 4 mg
Number of subjects: 120
Study 15150184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once a day
Number of subjects: 866
Study 15150184 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone, 1 g once a day
Number of subjects: 866
Study 11464117 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 25
Study 11464117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 25
Study 11464117 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS + Ondansetron
Number of subjects: 25
Study 9664225 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus probabilities (0.90/0.10, 0.80/0.20, 0.70/0.30, 0.60/0.40, 0.50/0.50 alternation, 0.50/0.50 random)
Number of subjects: 6
Study 9664225 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus probabilities
Number of subjects: 6
Study 8529737 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphuzosine
Number of subjects: 91
Study 8529737 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosine
Number of subjects: 91
Study 8529737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 2913182 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Medicine Clinic
Number of subjects: 520
Study 2913182 — intervention group
Group type: COMPARATOR
Intervention: Family Practice Clinic
Number of subjects: 520
Study 765292 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 30
Study 765292 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 30
Study 31279073 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF (800/150/200/10 mg)
Number of subjects: 1141
Study 31279073 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-switch to D/C/F/TAF (after 44 weeks of F/TDF)
Number of subjects: 1141
Study 31279073 — intervention group
Group type: COMPARATOR
Intervention: Boosted PI plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF)
Number of subjects: 1141
Study 28713645 — intervention group
Group type: EXPERIMENTAL
Intervention: Test agent (novel slowly dissolving adhering disc) plus oral hygiene self-care
Number of subjects: 5
Study 28713645 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene self-care only
Number of subjects: 5
Study 25733627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake <2300 mg/d
Number of subjects: 3982
Study 25733627 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing sodium intake >2300 mg/d
Number of subjects: 3982
Study 25733627 — intervention group
Group type: COMPARATOR
Intervention: MedDiet interventions with reduced sodium intake
Number of subjects: 3982
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged 55-65 years
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged 65-75 years
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with BMI ≥ 25 kg/m²
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with antihypertensive treatment
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents inland
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with moderate physical activity
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with high physical activity
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with glomerular filtration rate 60-90 ml/min per 1.73 m²
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with glomerular filtration rate < 60 ml/min per 1.73 m²
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with CT genotype at MTHFR 677C>T polymorphism
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with TT genotype at MTHFR 677C>T polymorphism
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (men)
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (women)
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with hypertension grade 3
Number of subjects: 13946
Study 22850357 — intervention group
Group type: EXPERIMENTAL
Intervention: Male non-drinkers
Number of subjects: 13946
Study 21663813 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.125 mg/kg/min for one minute and then 0.04 mg/kg/min)
Number of subjects: 42
Study 21663813 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 42
Study 19634511 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of clopidogrel
Number of subjects: 48
Study 19634511 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of clopidogrel
Number of subjects: 48
Study 19634511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 48
Study 16702890 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (37.5-300 mg/d)
Number of subjects: 538
Study 16702890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (25-200 mg/d)
Number of subjects: 538
Study 16702890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study 16702890 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 538
Study 16702890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 538
Study 15150566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraflex stent placement
Number of subjects: 209
Study 15150566 — intervention group
Group type: COMPARATOR
Intervention: Single-dose brachytherapy (12 Gy)
Number of subjects: 209
Study 11004862 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐OSA group (n = 35)
Number of subjects: 73
Study 11004862 — intervention group
Group type: COMPARATOR
Intervention: BO‐OSA group (n = 14)
Number of subjects: 73
Study 11004862 — intervention group
Group type: COMPARATOR
Intervention: O‐Z group (n = 24)
Number of subjects: 73
Study 9232360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state during exercise
Number of subjects: 10
Study 9232360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state during exercise
Number of subjects: 10
Study 9232360 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting SMA blood flow (fed)
Number of subjects: 10
Study 9232360 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting forearm and leg blood flow (FBF and LBF) and vascular resistance (FVR and LVR)
Number of subjects: 10
Study 8450402 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene, 180 mg/day
Number of subjects: 21
Study 8450402 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 3922052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (30 mg)
Number of subjects: 12
Study 3922052 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate ointment (100 mg)
Number of subjects: 12
Study 3922052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12